

AMP German Cannabis Group Receives Irradiation Licence for Medical Cannabis Imports into Germany

BERLIN, April 14, 2020 /CNW/ - AMP German Cannabis Group Inc. ("AMP" or the "Company") (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) is pleased to announce it has successfully obtained all the required licences to import, store at its licensed narcotic storage facility and distribute to its pharmaceutical distributors irradiated EU-GMP certified medical cannabis flower.

The Federal Institute for Drugs and Medical Devices (BfArM) granted an irradiation permit to AMP Alternative Medical Products GmbH ("AMP Germany"), a wholly-owned subsidiary of AMP, for the distribution of medical cannabis flowers that have undergone ionizing radiation treatment ("AMRadV License").

EU-GMP medical cannabis imported into Germany that does not comply with microbial levels as defined in general monographies of the European Pharmacopoeia must use microbial sterilization before being made available for sale in Germany's medical cannabis program. To date, all medical cannabis imported into Germany has been irradiated and requires an AMRadV License.

Dr. Stefan Feuerstein, President of AMP, commented: "Being granted an AMRadV Licence is an important and last step for AMP to be able to import from Europe and elsewhere. AMP will now complete the EU-GMP certification audit of its supply chain and start the process with the Netherlands Ministry of Health who supplies and organizes the export of medical cannabis flowers from the Netherlands. AMP is planning to start imports from the Netherlands in May and Canada during the latter part of this year."

About AMP German Cannabis Group Inc.

AMP German Cannabis Group is an import wholesaler of EU-GMP medical cannabis into Germany.

For more information, please visit: www.amp-eu.com.

AMP social media links: [Twitter](#), [LinkedIn](#), and [Facebook](#). Media Kit: www.amp-eu.com/media-kit

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements that are based on the Company's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

SOURCE AMP German Cannabis Group Inc.

View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/April2020/14/c7052.html>

%SEDAR: 00010076E

For further information: Mr. Alex Blodgett, CEO and Director, Telephone: +236-833-1602,
Canada: investor@amp-eu.com, Germany: investor@amp-eu.de

CO: AMP German Cannabis Group Inc.

CNW 03:00e 14-APR-20